Roche: UBS still on hold after Telavant acquisition
(CercleFinance.com) - The analyst confirms a neutral rating on the stock, with an unchanged target price of 280 Swiss francs (cp: 235 CHF, -1%), following Roche's announcement of the acquisition of Telavant Pharma.
"Roche jumps to the front of the anti-TL1A space with Phase III ready asset (US/Japan rights for >$7bn)", UBS says.
The acquisition of Telavant, a subsidiary of Roivant, includes the rights to RVT-3101, Roivant's new antibody to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
The Swiss healthcare group will obtain the rights to develop, manufacture and market RVT-3101 in the US and Japan for the treatment of inflammatory bowel diseases and potentially several other diseases.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"Roche jumps to the front of the anti-TL1A space with Phase III ready asset (US/Japan rights for >$7bn)", UBS says.
The acquisition of Telavant, a subsidiary of Roivant, includes the rights to RVT-3101, Roivant's new antibody to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
The Swiss healthcare group will obtain the rights to develop, manufacture and market RVT-3101 in the US and Japan for the treatment of inflammatory bowel diseases and potentially several other diseases.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.